Research Perspective|Volume 1, Issue 7|pp 674—677

CXCL5 drives obesity to diabetes, and further

Carine Chavey^1,^2,³, Lluis Fajas^1,^2,³

¹IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, F-34298, France
²INSERM, U896, Montpellier, F-34298, France
³Université de Montpellier1, Montpellier, F-34298, France

Received: June 18, 2009Accepted: July 1, 2009Published: July 2, 2009

Copyright: © 2009 Chavey et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

We have recently shown that the CXCL5 chemokine is secreted by adipose tissue in the obese state. We demonstrated that adipose tissue-derived CXCL5 mediates insulin resistance in muscle. We speculate in this paper that CXCL5 could also mediate other obesity, and diabetes-derived pathologies, such as cardiovascular disease, retinopathy, or inflammatory bowel disease. In this scenario CXCL5 targeted therapy would prevent not only the development of type II diabetes in obese subjects, but also several other obesity-related co morbidities. Finally we propose to analyze the CXCL5 gene to find particular polymorphisms that could predict the development of type II diabetes in obese subjects.